1.
IEAC组和CEAC组淋巴瘤患者的临床特征
Clinical characteristics of patients with lymphoma in IEAC and CEAC groups
| Clinical characteristics | IEAC group (n=43) | CEAC group (n=63) | P | ||
| Gender | |||||
| Male | 25(58.1%) | 41(65.1%) | 0.469 | ||
| Female | 18(41.9%) | 22(34.9%) | |||
| Age, year | |||||
| < 40 | 16(37.2%) | 25(39.7%) | 0.797 | ||
| ≥40 | 27(62.8%) | 38(60.3%) | |||
| Diseases | |||||
| B cell lymphoma | 36(83.7%) | 43(68.3%) | 0.073 | ||
| T cell lymphoma | 7 (16.3%) | 20(31.7%) | |||
| B-symptom | |||||
| Yes | 20(46.5%) | 25(39.7%) | 0.485 | ||
| No | 23(53.5%) | 38(60.3%) | |||
| Ann Arborstages | |||||
| I-II | 10(23.3%) | 15(23.8%) | 0.947 | ||
| III-IV | 33(76.7%) | 48(76.2%) | |||
| Lactate dehydrogenase | |||||
| > 250 U/L | 24(55.8%) | 33(52.4%) | 0.728 | ||
| ≤250 U/L | 19(44.2%) | 30(47.6%) | |||
| IPI score | |||||
| 0-2 | 27(62.8%) | 46(73.0%) | 0.264 | ||
| 3-4 | 16(37.2%) | 17(27.0%) | |||
| Disease status before ASCT | |||||
| CR | 33(76.7%) | 46(73.0%) | 0.592 | ||
| PR | 8 (18.6%) | 11(17.5%) | |||
| PD | 2(4.7%) | 6(9.5%) |